NEW YORK, Dec. 6, 2018
/PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") – a
leading investment bank, wealth manager, and a subsidiary of
Oppenheimer Holdings (NYSE: OPY) – today announced that
Kevin DeGeeter joined the Firm as
Managing Director and Senior Analyst of the Life Sciences research
team. DeGeeter will focus primarily on biotechnology, but will also
expand Oppenheimer's presence in molecular diagnostics.
"We are delighted to have Kevin return to the Firm in a senior
role on our Life Sciences research team," said Director of Equity
Research, John Parks. "Oppenheimer
has a long-standing commitment to the biotechnology industry, and
Kevin's addition allows us to significantly deepen our domain
expertise. His experience in the key subsectors of molecular
diagnostics, emerging technologies, infectious diseases, and of
course oncology, makes him the ideal addition as we continue to
expand our team."
With over two decades of buy- and sell-side experience, DeGeeter
will be responsible for expanding and differentiating Oppenheimer's
research product. He previously served as Managing Director at
Ladenburg Thalmann and has also held positions at J.P Morgan, Paine
Webber, Natixis Bleichroeder, and Manning & Napier Advisors. He
spent two years at Oppenheimer previously as a Senior Analyst.
"Right now, the opportunity in biotechnology and molecular
diagnostics is tremendous," said DeGeeter. "The rise of sequencing
technologies and new reimbursement models allows companies to
innovate how they're testing and matching the best drug for the
right patient to provide value. Also, the proliferation of
antibiotic-resistant bacteria presents new challenges and
opportunities for innovation within the space. I look forward to
helping our clients capitalize on these trends in personalized
medicine and molecular diagnostics."
DeGeeter earned his bachelor's degree in Economics from
Colgate University.
Oppenheimer & Co. Inc.
Oppenheimer & Co.
Inc. (Oppenheimer), a principal subsidiary of Oppenheimer
Holdings Inc. (OPY on the New York Stock Exchange), and its
affiliates provide a full range of wealth management, securities
brokerage and investment banking services to high-net-worth
individuals, families, corporate executives, local governments,
businesses and institutions.
View original
content:http://www.prnewswire.com/news-releases/oppenheimer-announces-strategic-addition-to-life-sciences-research-team-300760845.html
SOURCE Oppenheimer & Co. Inc.